Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant diseases with late diagnosis, rapid progression, high invasiveness, and early metastasis. Epithelial-to-mesenchymal transition (EMT) is a crucial step in metastasis that enables polarized immotile epithelial cells to gain fibroblast-like mesenchymal abilities such as enhanced motility. The dynamic process of EMT in PDAC with its powerful influence on disease progression and especially metastasis is of vigorous interest in biomedical research to elucidate its signaling pathways and regulation mechanisms. It is evident that epigenetics such as histone and DNA modification or noncoding RNAs such as microRNAs and long noncoding RNAs are of high importance in initiation and progress of EMT in PDAC. This review analyzes the latest research dealing with EMT and its epigenetic regulation in PDAC and summarizes its potentials in diagnostic, prognostic, and therapeutic management.
Pancreatic ductal adenocarcinoma (PDAC) as one of the most aggressive malignant tumors worldwide is the fourth leading cause of cancer-related death in western countries, and it is expected to rise to second place behind lung cancer until 2030. 1 In contrast to stable or declining trends for most cancers in Europe and the USA since 2009, PDAC shows an increase of about 5% for both genders with a 5-year relative survival rate of only 7%. [1] [2] [3] The reason behind its fatal prognosis is rapid disease progression and early metastasis leading to late diagnosis at advanced unresectable stages, and lack of effective therapy due to high chemoresistance. 4 Correspondingly, >80% of PDAC are diagnosed at a regional or distant metastasized level that limits patients' therapy options and survival dramatically. 1 Current therapy for PDAC is interdisciplinary and multimodal, consisting of oncological surgery, the only curative treatment option of PDAC at early stages, and chemotherapy. Though the overall survival is improved by adjuvant first-line chemotherapy, there is a strong inhomogeneity in response to the therapy among patients. 5, 6 Therefore, there is an urgent need to identify accurate diagnostic and therapeutic targets for PDAC to improve its poor prognosis. A crucial step toward metastasis is epithelial-to-mesenchymal transition (EMT) that enables polarized immotile epithelial cells to gain mesenchymal abilities such as leaving their cell layer and becoming invasive and motile 7, 8 ( Fig. 1) . A similar pattern of differentiation is seen in cancer stem cells (CSCs) that are the main boosters in tumor initiation and progress because of their mobility and common drug resistance. [9] [10] [11] EMT is physiological in embryonic development and wound healing, but also occurs in tumor progression as an early metastatic step. 12 The process of EMT can be identified by phenotypic changes and molecular reprogramming that leads to a switch in the cell's protein expression with a loss of epithelial markers such as E-cadherin, claudin, occludin, and cytokeratin and a strong elevation of mesenchymal markers such as vimentin, N-cadherin, and fibronectin. 7, 8 It is important to understand EMT as a dynamic process of cell differentiation which vitally goes in both directions -EMT and mesenchymalto-epithelial transition (MET). Therefore a cell can possibly be in a range of epithelial, mesenchymal or "hybrid/in-between" states, called "partial EMT." 13 The multimodal mechanism behind this process is complex and involves different pathways and regulators on the endocrine and autocrine levels as well as genetic and epigenetic alterations. 14, 15 Epigenetic changes are relevant alterations to the genome without a change in the nucleotide sequence. Prominent examples of epigenetic changes are DNA-(de)methylation, histone modification, and influence on the transcriptional and post-transcriptional level by noncoding RNAs such as microRNAs (miRs) or long noncoding RNAs (lncRNAs). Though the entire process of EMT and especially its initiation and regulation is not yet completely understood, recent studies revealed important pathways for EMT in PDAC, for example, transforming growth factor beta (TGF-b) and Wnt/b-catenin and linked them with regulatory epigenetic alterations conducted by miRs. 10, 16, 17 MiRs are 18-25 nucleotide long noncoding endogenous RNA sequences, that modulate gene expression by base pairing with complementary sequences in target messenger RNAs (mRNAs) leading to their silencing and degradation. 18 Emerging evidence suggests that epigenetic molecules might be useful marker tools for diagnosis, prognosis, and therapy response in PDAC. [19] [20] [21] [22] Especially miRs seem to be of high potential for the use as biomarkers and therapy targets because they are detectable in blood samples and stable towards laboratorial processes. This field of research is extremely important for clinical researchers, because carbohydrate antigen 19-9 (CA 19-9) as the currently most common diagnostic biomarker for PDAC has several limitations such as poor specificity and lack of expression in certain phenotypes. 22, 23 This review gives an overview of EMT and its epigenetics in PDAC and highlights its clinical potential.
Epithelial-to-Mesenchymal Transition in Pancreatic Carcinoma
PDAC remains a lethal disease because of its high metastatic potential due to potent invasiveness. The main step PDAC cells undergo on their way to metastasis is EMT. The process of EMT in PDAC with its low expression of epithelial and overexpression of mesenchymal markers is of prognostic value: Shin et al. demonstrated a significant better overall survival in PDAC patients with high expression of E-cadherin and low expression of urokinase plasminogen activator (uPA), a marker for metastasis and invasiveness, compared to the opposite expression pattern (18.7-7.5 months, p < 0.05). 24 Similarly, Javle et al. identified the EMTphenotype as a significant marker for bad prognosis in PDAC patients who underwent surgical resection. 25 In a study based on a rapid autopsy program for PDAC patients, 75% of the primary tumors with mesenchymal features developed metastatic lesions to the liver and lung. 26 Furthermore, EMT is linked with resistance to the common first-line chemotherapy with gemcitabine. 27 These results make the process of EMT clinically relevant in PDAC.
The development of a cell undergoing EMT is based on multiple stimuli and pathways. The whole process of EMT works very dynamically with multiple different stages and phenotypes between the epithelial and mesenchymal extremes. Those "hybrid"-or "partial EMT"-stages are more or less stable and fulfill different tasks on the cell's way to enhanced motility for leaving the primary tumor or to strong adhesive potential for forming a distant metastasis. 28, 29 One of the best-known and most important EMT inducers is TGF-b-signaling that plays a crucial role in the regulation of developmental patterning and morphogenesis, cell proliferation, differentiation, and disease pathogenesis. In the canonical TGF-b pathway, ligand binding to TGF-b receptors results in activation and phosphorylation of cytoplasmic signaling SMAD effector proteins. They dimerize with co-activating SMAD4 and translocate to the nucleus, where they stimulate transcription of target genes that lead to the invasive phenotype of PDAC with downregulation of epithelial markers and upregulation of mesenchymal markers. 30, 31 There is also a non-canonical SMAD-independent pathway of TGF-b signaling that promotes cytoskeletal rearrangement and adhesion that are important attributes in defining the cell's epithelial or mesenchymal state. 32 TGF-b and thereby the whole pathway is widely regulated (Fig. 2) . Hiraga et al. conducted a study with the PDAC cell line Panc-1 and human PDAC tissue samples to elucidate the role of NADPH oxidase 4 (NOX4)-generated reactive oxygen species (ROS) in TGF-b-induced EMT. They found a critical induction of EMT by ROS finally via activation of SNAIL, an important transcription factor that downregulates epithelial markers and upregulates mesenchymal markers. 33 Also using Panc-1 cells, Wu et al. showed a significant upregulation of basic-helix-loop-helix (bHLH) transcription factor DEC1 induced by TGF-b whereby the expression and the levels of nuclear, cytoplasmic, or membrane localization 
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Tr€ ager and Dhayat of EMT-related factors, including phosphorylated SMAD3, SNAIL, claudin-4, and N-cadherin get elevated. 34 Furthermore, TGF-b-mediated EMT was shown to be regulated by several miRs: miR-367 35 and miR-10b 36 increase TGF-b induced transcriptional activity, and miR-15b inhibits the TGF-b-inhibitor SMURF2. 37 On the other side, TGF-bmediated EMT is suppressed by miR-373 38 and miR-655. 39 TGF-b itself downregulates the expression of the miR-200-family that is of extreme importance in inhibition of EMT. 40 Moreover, TGF-b receptors might be potential therapeutic targets as demonstrated by Hagopian and Brekken who showed that antibody-mediated inhibition of stromal TGF-breceptor-2 reversed epithelial plasticity resulting in a potent reduction of metastasis in xenograft models of PDAC. 41 TGF-b is closely linked to other pathways that regulate EMT. For example, Gli1, a critical transcription activator of the Sonic Hedgehog (Shh) signaling pathway, promotes TGFb 42 and TGF-b itself induces tyrosine phosphorylation of a-catenin and the downstream Wnt target b-catenin in a SMAD-independent manner. 43 The Wnt/b-Catenin pathway regulates amongst others stem cell pluripotency and cell fate decisions. At the end of the pathway stands the stabilization and nuclear translocation of the transcriptional co-activator b-Catenin that promotes the transcription of genes that regulate proliferation and differentiation such as SNAIL, ZEB1, and Slug. b-Catenin is also very important in the planar-cellpolarity pathway regulating cell-cell contact via adherent junctions. 32 However, the regulation of Wnt/b-Catenin pathway consists of multiple effectors including epigenetics (Fig.  2) . MiR-27, miR-197, and miR-374a 16 activate expression of b-Catenin, while miR-33a suppresses it, 44 and miR-383 negatively influences the pathway because it suppresses the Wnt/ b-Catenin-activator ROBO3. 45 Additional activators are the S100 calcium-binding protein A6 46 and Leucine-rich repeat flightless-1-interacting protein 1 (LRRFIP1). 47 EMT in PDAC is regulated and activated by other pathways as well, among them hippo, 48 NFkB/hypoxia, 49 and Notch-1. 50 This complexity shows that EMT is a strictly regulated mechanism of outstanding importance for PDAC cells. Although not all pathways and their regulation are fully elucidated, it is evident that epigenetic regulation plays a crucial role in both activation and repression of EMT in PDAC. Besides influencing several pathways leading to EMT, epigenetic molecules regulate a certain group of transcription factors, called EMT-inducing transcription factors (EMT-TFs). EMT-TFs are transcription factors that regulate the transcription of genes coding for proteins that are important for EMT such as E-Cadherin, N-Cadherin, or vimentin. There are three groups of EMT-TFs: zinc fingers (e.g. SNAIL and Slug), two-handed-zinc-fingers (e.g. ZEB1 and ZEB2), and basis-helix-loop-helix transcription factors (e.g. TWIST). Because of their similar promoting effect on EMT in PDAC, some EMT-TFs are regulated simultaneously by the same one molecule: e.g. integrin b4 (ITGB4) lowers expression levels of SNAIL, ZEB1, and ZEB2. 51 GATA6, a transcription factor of the GATA-family with direct proepithelial function, inhibits the mesenchymal transformation.
52 Figure 3 shows the regulation of EMT-TFs and their regulatory effects on EMT.
A master regulator of EMT is the SNAG domain containing zinc finger protein SNAIL that is regulated by numerous molecules and pathways. By directly binding to the E-cadherin gene promoter SNAIL represses its transcription and convert normal epithelial cells into mesenchymal cell phenotype. [53] [54] [55] [56] Zinc-finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) are further crucial regulators of EMT and metastasis because they interfere both with the expression of epithelial and mesenchymal markers. Furthermore ZEB1 forms an important double-negative feedback loop with the miR-200-family that is a strong stabilizer of the epithelial state.
72 ZEB1 is also negatively regulated by miR-652. 65 ZEB-induced EMT is promoted by overexpression of macrophage migrationinhibitory factor (MIF) 70 and carcinoembryonic antigen-related cell adhesion molecule 6 (CAECAM6). 71 Because of their importance in EMT regulation, ZEB transcription factors are also regulated by molecules involved in other EMT-related pathways: TGF-b, tumor necrosis factor alpha (TNF-a), Interleukin 1 (IL 1), and hypoxia signals directly upregulate ZEB2 to induce EMT, growth arrest, and senescence, whereas Hedgehog signals indirectly upregulate ZEB2 via TGF-b. 73 Another group of transcription factors involved in EMT in PDAC are basic helixloop-helix transcription factors, of which TWIST and ETV1 are important members that promote EMT in PDAC. 74, 75 EMTTFs also play a role in regulation of CSCs to catalyze their potentials in mobility which once again shows the correlation between EMT and CSCs. 76, 77 This correlation strongly stresses out the clinical importance of EMT because the most promising method in cancer therapy is tackling CSCs. To achieve this challenge, the process of EMT and its regulatory molecules such as EMT-TFs could be the key.
Epigenetic Regulation of Epithelial-to-Mesenchymal Transition in Pancreatic Carcinoma
Above the different pathways that organize the multimodal process of EMT in PDAC and its regulation by transcription factors, cytokines, and other endocrine molecules, strong influence exists from the epigenetic level. Epigenetics interfere with nearly all biochemical processes by relevant alterations to the genome without a change in the nucleotide sequence. Three main groups that are shown to sustainably regulate EMT in PDAC are noncoding RNAs such as miRs or lncRNAs, DNA-(de)methylation, and modification of histones.
MiRs are short non-coding, single-stranded RNAs of 18-25 nucleotides that bind to mRNAs leading to their translational repression or degradation depending on the level of complementarity. Currently, >2,500 potential human mature miRs have been recorded in miRbase and their number is increasing steadily. The fact that one miR targets many different mRNAs and one mRNA is targeted by a lot of miRs describes the importance of miRs for biochemical processes. Thus, there is a need for research on miRs and for validation of their targets and effects. Chitkara et al. recently reviewed the impact and significance of miRs in PDAC and their therapeutic potential. 19 Hawa et al. worked out the duality of miR function as oncogenous and tumor suppressive molecules 78 while Tang et al.
highlighted the importance of miRs in the process of EMT in human cancers. 16 Table 1 gives an overview of miRs that specifically take part in the regulation of EMT in PDAC. Recently, another family of noncoding RNAs has been described to take part in regulation of EMT in PDAC: long noncoding RNAs (lncRNAs). LncRNAs are >200 nucleotides long and are involved in gene expression regulation as well on the transcriptional and post-transcriptional level as in the epigenetic field. Until today, lncRNA database lncRNAdb lists nearly 200 functional lncRNAs in humans. Jiao et al. found the lncRNA metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) to be significantly upregulated in PDAC tissue and cell lines compared to non-cancerous controls. Functional tests revealed that the oncogenic potential of MALAT-1 at least partially consists of EMT induction and enhancement of CSC phenotypes. 79, 80 Furthermore, multivariate analysis showed an independent unfavorable prognostic impact of MALAT-1. 81 Li et al. had similar results in their study focusing on the lncRNA HOTTIP in PDAC tissue and cell lines and were able to connect it to EMT and poor survival in PDAC patients. 82 Although research on lncRNAs in PDAC is still in the beginning and their functional role and 
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Promoting EMT fi "oncogenic miRs" Suppressing EMT fi "tumor suppressive miRs" precise regulatory effects especially in EMT in PDAC are still unexplored, the first microarray screening datasets are available and show thousands of lncRNAs to be dysregulated in PDAC compared to non-cancerous controls. 83 DNA-(de)methylation describes the addition or removal of methyl groups to certain nucleobases of the DNA strand. This process influences the transcriptional potential of the DNA without changing the nucleotide sequence and is an important feature of the epigenetic code. These changes in the methylation pattern are known to play a crucial role in tumorigenesis and cancer progression. 84 Thus more and more research in the field of PDAC focuses on DNA-(de)methylation. Nagpal et al. established a platform called Pancreatic Cancer Methylation Database with >65,000 entries for the methylation status of over 4,000 unique genes. 85 Among these are also genes coding for important regulatory proteins of EMT in PDAC: TWIST, HDAC1, Shh, HIF-1, Notch-1, Wnt, and ZEB1/2. Especially TWIST's methylation pattern in PDAC has been widely described in tissue samples and different PDAC cell lines. 86 Above this fundamental research, DNA methylation patterns, including EMTrelevant genes, have been successfully evaluated for clinical use as biomarkers for early detection and prognosis of PDAC. [87] [88] [89] Besides noncoding RNAs and DNA-(de)methylation, histone modification plays a major role in epigenetic regulation of EMT in PDAC. Histones are proteins that package and structure the DNA in units, called nucleosomes. As the way of packaging DNA regulates how easy the DNA can be read and transcript, histones are central contact points to be modified to make a specific part of DNA transcriptable or to package it tightly and thereby suppress its transcription. Histones can be modified in their activity, for example, by alteration of their methylation, acetylation, phosphorylation, or ubiquitination. 90 The influences of these alterations on the process of EMT in PDAC are of high research interest, especially because it may be useful for therapy. In a study by Aghdassi et al. histone deacetylase 1 and 2 (HDAC 1/2) were found to play a crucial role in E-Cadherin expression. Accordingly, HDAC 1 and 2 are associated with ZEB1 on the CDH1 promoter region of E-Cadherin and radically lower ECadherin expression in human PDAC resection specimens and cell lines. Furthermore silencing of ZEB1 resulted in reexpression of E-Cadherin and treatment with specific histone deacetylase inhibitors attenuated tumor cell migration and proliferation.
91 SIRT1 is a mammalian NAD 1 -dependent class III HDAC that catalyzes EMT by inducing TGF-b1. 92 Von Burstin et al. detected a similar clinical usage of HDAC inhibitors and elucidated a cooperation of HDAC 1 and 2 with SNAIL in silencing E-Cadherin in human and murine pancreatic tissue. 56 Chen et al. described a connection between SNAIL and histones via ubiquitination of histone H2A and thus lower E-Cadherin. Furthermore, they identified a number of other SNAG-associated histone modification complexes such as Sin3A-HDAC1/HDAC2, EZH2/SUZ12, LSD1-CoREST, and Ajuba-PRMT5. 93 Moreover histonedemethylization and histone-ubiquitination are described in PDAC: Lysine (K)-specific demethylase 4B is a histone H3K9 demethylase and is demonstrated to upregulate the expression of ZEB1 in the TGF-b-induced EMT process. 94 USP22, a ubiquitin-specific peptidase that belongs to the deubiquitinating enzyme family and serves as a subunit of the hSAGA complex, deubiquitinates the H2A and H2B histone proteins and acetylates the H4 histone protein that leads to EMT. 69 Interestingly, H2AK119Ub1, 93 a status of monoubiquitination of histone H2A at lysine 119 that is linked to SNAIL, and high levels of integrin b4 (ITGB4) 51 and ZEB1 95 tested in surgical resection specimens correlated with poor survival in PDAC.
Strong evidence in numerous publications shows that epigenetic molecules might be not only potential biomarkers for earlier diagnosis and chemotherapy response but also promising targets for modern approaches in therapy of PDAC. 19, 20, 55, 96, 97 Schultz et al. conducted a case-control study with whole blood samples of patients with PDAC (n 5 409), pancreatitis (n 5 25), and healthy participants (n 5 312) aiming to detect miRs that could be used as diagnostic biomarkers for PDAC. 754 miRs have been tested and two panels including EMT-related miR-126 and miR-150 were found to be potentially useful as a combination partner for CA 19-9 towards a more specific and sensitive diagnosis of PDAC. 96 Furthermore, different miRs were described as prognostic markers: low miR-192, 62 high miR-196a-2, 98, 99 and low miR-335 100 are unfavorable factors for patient's prognosis, while high levels of miR-200c were associated with significantly better survival rates. 101, 102 Recently, we could identify miR-21 and miR-100 as unfavorable prognostic factors markers for overall survival and chemotherapy response in adjuvant-treated PDAC UICC stage II patients. 103 Correspondingly to the fact that many epigenetic molecules are involved in pathways that lead to PDAC drug resistance Ma et al. highlighted the important role of miR-223 in gemcitabine resistance 104 while miR-320a promotes 5-FU resistance. 105 The crucial step in management of PDAC after diagnosis is therapy. Klieser et al. reviewed the up-to-date situation of HDAC inhibitors and resumed that at the moment no drug has been approved for PDAC therapy, but there are clinical trials with promising candidates. Vorinostat which has received approval for treatment of cutaneous T-cell lymphoma in the US significantly sensitized PDAC cells, Panobinostat induced the death of PDAC cells by apoptosis and the combination of Mocetinostat and Gemcitabine might be effective for gemcitabine-refractory PDAC. 55 Zheng et al. once more focused on EMT in chemoresistance of PDAC and thus stressed out the urgent importance of combining EMT inhibition with chemotherapy to get an improved response to chemotherapy and thereby a better therapy success. 106 A few clinical trials are focusing on EMT-related signal pathways in therapy of PDAC targeting the Wnt-pathway or inhibiting TGF-b and Notch pathways in metastatic PDAC stages. 107 
Conclusion
Accumulating evidence in recent years indicates that EMT is a critical process not only in the context of normal cell differentiation during embryonic development but also in carcinogenesis with dissolution of epithelial integrity, increased migration, local invasion, and metastasis. Numerous evidences suggest that EMT can be regulated by the cooperation of different signaling pathways on common targets. Moreover, epigenetic changes including DNA and histone modification and alternations of noncoding RNAs are involved in the stepwise progression and regulation of EMT. Many prevailing studies point out the multimodal and dynamic character of EMT and the connection of all the different regulatory networks. This fact urges to see EMT in the big picture instead of focusing on tiny details.
Nevertheless, recent studies spread optimism that epigenetic molecules might be of vigorous clinical use as biomarkers for earlier diagnosis and for more reliable prediction of prognosis and therapy-response of PDAC patients at risk of developing drug resistance and metastasis. Understanding the molecular mechanisms responsible for EMT in PDAC patients will be essential for the discovery of new strategies to prevent EMT-associated cancer progression and to design new therapies. However, the underlying (epi-)genetic mechanisms are still not fully elucidated and clinical implementation in PDAC treatment is still pending. More research is strongly indicated to solve the puzzle of EMT and get the whole picture to successfully continue on the path towards more reliable biomarkers and customized therapy options for PDAC patients.
